Kerstin Michalski
Overview
Explore the profile of Kerstin Michalski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heinrich M, Blickle E, Hartrampf P, Hasenauer N, Kosmala A, Kerscher A, et al.
Eur J Nucl Med Mol Imaging
. 2025 Mar;
PMID: 40088267
Purpose: The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical I single photon emission computed tomography/computed tomography (SPECT/CT) after the first...
2.
Kosmala A, Hasenauer N, Serfling S, Michalski K, Frohlich M, Dreher N, et al.
Theranostics
. 2025 Jan;
15(3):804-814.
PMID: 39776816
To establish the extent, distribution and frequency of in-vivo vessel wall [Ga]Ga-PentixaFor uptake and to determine its relationship with calcified atherosclerotic plaque burden (CAP) and cardiovascular risk factors (CVRF). 65...
3.
Michalski K, Kosmala A, Hartrampf P, Heinrich M, Serfling S, Schlotelburg W, et al.
J Nucl Med
. 2024 Oct;
65(12):1899-1903.
PMID: 39477500
We aimed to quantitatively investigate the prognostic value of PET-based biomarkers on [F]FDG and [Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in patients with highly aggressive neuroendocrine neoplasms (NENs) and to...
4.
Wielenberg C, Fostitsch J, Volz C, Marks R, Michalski K, Wasch R, et al.
Nuklearmedizin
. 2024 Apr;
63(4):252-258.
PMID: 38593856
Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in...
5.
Hartrampf P, Huttmann T, Seitz A, Kubler H, Serfling S, Higuchi T, et al.
J Nucl Med
. 2024 Mar;
65(4):560-565.
PMID: 38453363
In metastatic castration-resistant prostate cancer (mCRPC) patients treated with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), the recently proposed criteria for evaluating response to PSMA PET (RECIP 1.0) based on...
6.
Michalski K, Schlotelburg W, Hartrampf P, Heinrich M, Serfling S, Buck A, et al.
Mol Imaging Biol
. 2024 Feb;
26(2):344-350.
PMID: 38332341
Background: Gastro-entero-pancreatic neuroendocrine carcinomas (GEP-NECs) are an aggressive subgroup of neuroendocrine neoplasms (NENs). In patients affected with NEN, there is a growing body of evidence that increased C-X-C motif chemokine...
7.
Michalski K, Schlotelburg W, Hartrampf P, Kosmala A, Buck A, Hahner S, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256859
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC...
8.
Michalski K, Kosmala A, Werner R, Serfling S, Seitz A, Lapa C, et al.
Ann Nucl Med
. 2023 Oct;
38(2):87-95.
PMID: 37891376
Background: Two randomized clinical trials demonstrated the efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PSMA RLT) in metastatic castration-resistant prostate cancer (mCRPC). While the VISION trial used criteria within...
9.
Hartrampf P, Serfling S, Michalski K, Buck A, Werner R
Semin Nucl Med
. 2023 Jun;
54(1):69-76.
PMID: 37357025
Prostate-specific membrane antigen (PSMA) PET/CT has been widely integrated into the management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly used for initial staging in high-risk patients prior...
10.
Hartrampf P, Huttmann T, Seitz A, Kubler H, Serfling S, Schlotelburg W, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jun;
50(11):3465-3474.
PMID: 37272956
Background: Quantification of [ Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [F]-labeled radiotracers, we aimed to...